Tanglou directly fired the diagnostic technique:

[Patient: Guo Caier, female, 30 years old

Symptoms: swollen and allergic lips...

Diagnosis: Yida syndrome, crayfish allergy causing lip edema.】

Tanglou glanced at Guo Cai'er's lips again speechlessly. They were exactly the same as when Zhang Yida was allergic to crayfish. He said happily: "Don't worry, I looked at your symptoms. It should be crayfish allergy."

, it’s no big deal.”

Hearing what Tang Lou said, Guo Cai'er realized that he had called a lot of crayfish last night in a daze. Fortunately, fortunately.

After all, everyone in the general surgery department knew about Tang Lou and Cheng Sisi. How could she, Guo Cai'er, do that kind of thing? Although she didn't mind rubbing Tang Lou gently, slowly, wiping and picking...

"Then I'll leave first."

Tanglou confirmed that nothing happened last night, breathed a sigh of relief, and fled out of Cheng Sisi's room as if running away. He must stay away from Guo Caier in the future.

Looking at Tanglou who was escaping in a hurry and how happy he was to know that the two of them were safe and sound, Guo Caier didn't know whether it was peace of mind or regret. He touched his sausage mouth and said, "Hiss, it hurts me to death."

...

...

Tanglou took a drip and hurried back to his dormitory, washed up, and then rushed to the First City Hospital.

However, what he didn't expect was that when he walked into the gate of the First Hospital of the City, he saw a long banner that read: "Congratulations on the establishment of a provincial key discipline in the field of acute abdomen in the General Surgery Department of the First Hospital of the City.

success."

"Have you selected key subjects?"

Tanglou was surprised and happy. This was something that Director Cheng had been looking forward to, but he didn't expect to confirm it before he went to Zijingang Medical College for further studies.

[Ding, help the General Surgery Department of the First Hospital of the City successfully establish a provincial key discipline, task reward: storage column +10]

After reading this, Tanglou's heart skipped a beat. This was really a big deal. Speaking of which, he had obviously felt that there were not enough storage columns recently. This time, he added 10, which really solved a big problem.

Tanglou thought about it for a while and instead of going to the cardiovascular department, he went directly to Cheng Jian's office in the general surgery department to express his congratulations.

After knocking on the door and entering the tenement building, the director, deputy director, and various attending physicians of the general surgery department were all in Cheng Jian's office.

Everyone was celebrating, and everyone was overjoyed when they saw the tenement building.

"Tanglou, you are finally here. This time our department was able to successfully establish a provincial subject point, and you are indispensable."

Qingping saw Tanglou and came over to greet him, his eyes full of praise and appreciation.

"Yes, Dr. Tang, this time it really all depends on you. In addition to your improved new surgery, this time the president, vice president and directors of the Provincial Medical Association unanimously approved the decision of our city's first hospital.

The establishment of key disciplines. Among them, especially the recommendations and proposals of Professor Liu Pingguo, Professor Wen Dalong, and Director Chen Qilong directly set the tone of the entire meeting."

"Professor Liu said that in addition to the newly developed surgical procedures and the potential of our department, the most important thing is that they are unanimously optimistic about you!"

Hang Cuishan said very excitedly on the side, no one expected that Tanglou would have such influence in the Provincial Medical Association.

"Tanglou, Director Cheng and Director Shen just discussed together and planned to recommend you as the leader of the key disciplines of general surgery in the city's first hospital. Of course, all this will be officially appointed after you return from Zijingang Hospital."

Yan Ruoyun also said very seriously.

Hearing these big shots from the general surgery department, Tang Lou was extremely surprised. He turned out to be the leader of a key discipline this time?

"Director Cheng, Director Shen, I'm afraid this isn't appropriate. After all, I'm too junior and I'm afraid I can't take on this important responsibility."

Tanglou thought for a while and was ready to refuse. After all, the leader of the subject, no matter which department he was in, was the most respected doctor. After all, he was too young.

"Tanglou, please stop being modest. With your academic achievements and future potential, besides you, who else in the department would dare to be the leader of this department? If you can't do it, then who can? Tanglou, this matter, That's it. I've reported it to Director Yang a long time ago, and Director Yang also means the same thing. When you return from Zijingang Hospital this time, you will be appointed deputy chief physician."

Cheng Jian made the final decision.

Director Shen on the side also agreed very much. In fact, this matter had been discussed with the top management of the hospital. Originally, the hospital wanted to take it a step back, but after learning that Tanglou had directly become Professor Liu Juzi’s doctoral student, he became the director again. The special issue of "Chinese Journal of Cardiovascular Diseases" shows that there is no hospital that does not want to try its best to retain promising doctors and scientific research talents like Tanglou.

The subject leader of general surgery is undoubtedly the most suitable and the most affectionate person in Tanglou.

Now the appointment of the academic leader of Tanglou and the deputy director after returning from further studies are just to stabilize Tanglou.

"Tanglou, if you don't accept it, Director Cheng won't worry about letting you go to Zijingang Hospital for further study."

Qingping said quietly with a straight face.

"Okay, Director Cheng, don't worry, doctors. After I complete my further studies, I will definitely return to the First Hospital of the City. After all, Hecheng is my root."

After hearing what Tanglou said, all the doctors were very satisfied.

...

...

Originally, Tanglou had to learn the procedures for going to Zijingang Hospital for further study. However, because he was featured in a special issue of the "Chinese Journal of Cardiovascular Diseases" and with the help of Professors Liu Juzi and Liu Pingguo, Tanglou's trip to Hangzhou was immediately put on the agenda.

And Tanglou also had preliminary ideas about the subject that he would go to Zijingang Hospital and study under Liu Juzi.

He is planning to research and develop new drugs, and his main research area is antihypertensive drug CCB preparations.

Under the one-star anti-hypertensive drug CCB research and development technology (one-star, 3), Tanglou also has a general understanding of the research and development of new drugs.

The process from research and development to marketing of conventional new drugs is a very complicated process, and the financial investment involved is also very staggering. Moreover, a lot of manpower and material resources are often invested, and very few drugs can be successfully launched in the end.

It can be said that there is a narrow escape from death. The whole process is generally divided into the following stages:

A. The first is basic research. This process starts with patients, clinical pathology, and statistical data to find and verify potential targets.

B. Pharmacology and biomarker development. Including pharmacology and druggability research on targets, and biomarker research related to targets and prognosis.

C. Discovery of lead compounds. Lead compounds are compounds with certain biological activity obtained through various pathways and means. They are usually obtained through in vitro screening and used for further structural modification and optimization.

D. Optimization of lead compounds, confirmation of preclinical candidate compounds, and preclinical research, production and quality control (CMC) to support the application. In this link, potential drug candidate molecules are screened and systematic pharmacodynamic studies and toxicology studies are conducted. , it is also necessary to produce samples to support clinical research under quality management (GMP) conditions.

E. Clinical research. It mainly conducts clinical trials, including phase I, phase II, and phase III clinical trials. Each phase has different goals and different scales.

F. Regulatory approval. The main goal of this stage is to register and apply for drug marketing. The United States applies to the FDA, the European approval unit is EMA, and China applies to the State Drug Administration (DA).

G, post-marketing monitoring. It mainly monitors all information related to drugs after marketing, including effectiveness, safety, racial differences, non-standard use, etc.

H, medical picture. Including competition situation, pricing strategy, market share, doctor education, etc. These determine the commercial success of the drug.

The development of a drug from its source to phase 3 clinical trials is a costly process. The world's pharmaceutical giants have calculated that a new drug costs hundreds of millions of dollars on average.

Drug research and development is an industry with high investment, high risks and high returns. Once the drug is successfully launched, the returns will be staggering.

There is a word in the industry called "blockbuster", which refers to a drug with annual sales of more than 1 billion US dollars. An extreme example is Pfizer's patent-protected anti-lipid drug Lipitor. In 2010, global sales

The amount is US$10.133 billion.

It is foreseeable that as long as Tanglou's anti-hypertensive drug CCB is successfully developed and approved for marketing, it will definitely be a blockbuster drug!

Now, Tanglou has solved the preliminary basic research, discovery of lead compounds and confirmation of preclinical candidate compounds under the antihypertensive drug CCB research and development technology. What he has to do is to start with animal experiments and form complete experimental data.

Then gradually carry out human experiments.
Chapter completed!